SOLICITATION NOTICE
65 -- OptoSelect 11K Chips compatible with Opto Plasma B Discovery 2.0 on the Beacon Platform
- Notice Date
- 8/20/2020 11:20:03 AM
- Notice Type
- Combined Synopsis/Solicitation
- NAICS
- 325414
— Biological Product (except Diagnostic) Manufacturing
- Contracting Office
- NATIONAL INSTITUTES OF HEALTH NIAID BETHESDA MD 20892 USA
- ZIP Code
- 20892
- Solicitation Number
- NOI-NIAID-2041136
- Response Due
- 8/25/2020 2:00:00 PM
- Archive Date
- 09/09/2020
- Point of Contact
- Dana Monroe, Phone: 4063759814
- E-Mail Address
-
dana.monroe@nih.gov
(dana.monroe@nih.gov)
- Description
- PRE-SOLICITATION NOTICE NOI-NIAID-2041136 NAICS � 325414 This is a Notice of Intent, not a request for proposal.� The National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) intends to negotiate on an other than full and open competition basis with Berkeley Lights, Inc to procure a series of OptoSelect 11K chips for antibody array analysis. The Immunopathogenesis Section within NIH/NIAID is performing research for use in the NIH Clinical Research Center.� Required are OptoSelect 11k chip in multiple quantities as needed for specific profiling projects. These chips are compatible with Opto Plasma B Discovery 2.0 on the Beacon platform. Plasma B Discovery on the Beacon system enables automated, direct screening of B cells immediately after organ harvest and cell purification. B cells can be screened from multiple organs (spleen, bone marrow, lymph nodes) and cultured for multiple days in specialized media to enable multiple screens from a single cell sample. This platform allows thousands of potential hits to be found in days, not months. Every antibody sequence can be mapped directly to a known antibody function. Sequence relationships identify individual mutations that confer antigen specificity, cross-reactivity, and function. The Opto Plasma B Discovery Workflow enables down-selection of lead candidates through multiple assays for antigen specificity and function. Plasma B cells are screened using binding and functional assays to select only the most qualified antibody lead candidates. With a NanoPen chamber volume of only 250 pico liters, reactions are fast and precise. Complete assays in less than 1 hour, then chips can be reset to enable the next assay to begin. All this provide an unparalleled profile and characterization upfront that reduces cost and time expense of having to sequence or clone irrelevant non-functional hits. The statutory authority for this sole source requirement is 41 U.S.C. 253 (c) (1) as implemented by FAR 13.106-1 only one responsible source and no other supply of service will satisfy agency requirements. THIS IS NOT A REQUEST FOR PROPOSAL.� All responsible sources that could provide comparable services may submit a capability statement that will be considered by email (subject line to reference NOI-NIAID-2041136 to Dana Monroe at dana.monroe@nih.gov by Tuesday, August 25, 2020, 5:00pm eastern daylight savings time.� All responses received by the closing date of this synopsis will be considered by the Government.� A determination not to compete this requirement, based upon responses to this notice, is solely within the discretion of the Government.
- Web Link
-
SAM.gov Permalink
(https://beta.sam.gov/opp/f53f75b0a3704dd4bce3181298855676/view)
- Place of Performance
- Address: Bethesda, MD 20892, USA
- Zip Code: 20892
- Country: USA
- Zip Code: 20892
- Record
- SN05767918-F 20200822/200820230157 (samdaily.us)
- Source
-
SAM.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's SAM Daily Index Page |